Core Viewpoint - RenovoRx, Inc. is actively commercializing its FDA-cleared drug-delivery device, RenovoCath, and is presenting at the iAccess Alpha Virtual Best Ideas Fall Investment Conference to discuss its commercialization efforts and ongoing clinical trials [1][2][3] Company Overview - RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, a patented drug-delivery device that addresses high unmet medical needs [6] - The company utilizes its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for targeted therapeutic delivery, aiming to improve safety and efficacy compared to traditional systemic therapies [6] Commercialization Efforts - The company has received its first commercial purchase orders for RenovoCath devices as of December 2024, with several customers initiating repeat orders [9] - RenovoRx is expanding its customer base, including high-volume National Cancer Institute-designated centers, to meet anticipated demand for RenovoCath [10] Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the intra-arterial gemcitabine delivered via RenovoCath for treating locally advanced pancreatic cancer (LAPC) [3][7] - The Data Monitoring Committee has recommended continuing the trial after reviewing a second pre-planned interim analysis triggered by 52 deaths [3] Product Information - RenovoCath is designed for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including temporary vessel occlusion and chemotherapeutic drug infusion [5] - The combination product candidate, IAG, which uses RenovoCath, has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8]

Core Viewpoint - Citius Oncology is preparing for the U.S. commercial launch of its product LYMPHIR, expected in the fourth quarter of 2025, having raised significant capital to support pre-launch activities and secured distribution agreements with global providers [2][5]. Financial Highlights - Citius Pharmaceuticals raised $12.5 million in gross financings during the quarter, with an additional $9 million raised by Citius Oncology in July 2025 [1]. - For the fiscal third quarter ended June 30, 2025, the company reported a net loss of $5.4 million, or $0.08 per share, compared to a net loss of $4.8 million, or $0.07 per share, for the same period in 2024 [7][11]. - Research and development expenses were $938,000 for the quarter, down from $1.1 million in the same quarter of 2024 [7]. - General and administrative expenses increased to $1.9 million from $1.5 million year-over-year [7]. - As of June 30, 2025, the company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding [7]. Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [5]. - The company has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use, which support its competitive positioning [5].

Company Overview - Citius Oncology, Inc. is a platform focused on developing and commercializing novel targeted oncology therapies, with its primary asset, LYMPHIR, approved by the FDA for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) [5] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [5] - Citius Pharmaceuticals, Inc. owns 92% of Citius Oncology and is dedicated to developing first-in-class critical care products [6] Recent Offering - Citius Oncology announced the closing of a public offering of 6,818,182 shares of common stock at a price of $1.32 per share, generating gross proceeds of approximately $9.0 million [1][2] - The offering included warrants to purchase shares at the same exercise price of $1.32, which are immediately exercisable and expire five years from issuance [1] Use of Proceeds - The net proceeds from the offering will primarily support the commercialization of LYMPHIR, including milestone and royalty payments under existing license agreements, as well as for working capital and general corporate purposes [2] Regulatory Information - The securities were offered under a registration statement filed with the U.S. Securities and Exchange Commission (SEC), which was declared effective on July 16, 2025 [3]